𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Rasagiline (Azilect): new MAO-B inhibitor for Parkinson's disease

✍ Scribed by David Brooks

Book ID
112180200
Publisher
Wiley (John Wiley & Sons)
Year
2006
Tongue
English
Weight
75 KB
Volume
17
Category
Article
ISSN
0959-6682

No coin nor oath required. For personal study only.

πŸ“œ SIMILAR VOLUMES

Effects of tyramine administration in Pa
Effects of tyramine administration in Parkinson's disease patients treated with selective MAO-B inhibitor rasagiline
✍ J. Antonelle deMarcaida; Steven R. Schwid; William B. White; Karen Blindauer; St πŸ“‚ Article πŸ“… 2006 πŸ› John Wiley and Sons 🌐 English βš– 76 KB

## Abstract Rasagiline is a novel, potent, and selective MAO‐B inhibitor shown to be effective for Parkinson's disease. Traditional nonselective MAO inhibitors have been associated with dietary tyramine interactions that can induce hypertensive reactions. To test safety, tyramine challenges (50–75

MAO-B inhibitors for the treatment of Pa
MAO-B inhibitors for the treatment of Parkinson's disease
πŸ“‚ Article πŸ“… 2002 πŸ› John Wiley and Sons 🌐 English βš– 88 KB

## INTRODUCTION BACKGROUND Early attempts to enhance dopaminergic neurotransmission through inhibition of one of dopamine's major metabolizing enzyme -monoamine oxidase (MAO) -were made soon after the discovery of the striatal dopaminergic deficit and the efficacy of L-dopa. 1 However, side-effect